Overall survival rate (%) | Cancer-specific survival rate (%) | |||
---|---|---|---|---|
5 years | 10 years | 5 years | 10 years | |
All stages | ||||
LND status | ||||
LND | 41.5 | 26.2 | 65.8 | 60.3 |
No LND | 47.1 | 29.2 | 74.3 | 67.8 |
LND extent | ||||
No LND | 47.1 | 29.2 | 74.3 | 67.8 |
Limited LND | 39.2 | 24.3 | 63.5 | 57.1 |
Extended LND | 44.9 | 28.5 | 69.0 | 65.0 |
Lymph node stage | ||||
pN0 | 52.0 | 32.5 | 76.8 | 71.9 |
pNx | 47.1 | 29.2 | 74.3 | 67.8 |
pN1–3 | 20.7 | 13.8 | 40.1 | 34.2 |
pT1 stage | ||||
LND status | ||||
LND | 66.3 | 46.3 | 87.6 | 86.1 |
No LND | 64.5 | 41.5 | 88.9 | 83.1 |
LND extent | ||||
No LND | 64.5 | 41.5 | 88.9 | 83.1 |
Limited LND | 64.1 | 43.6 | 84.7 | 83.4 |
Extended LND | 68.9 | 50.9 | 91.0 | 89.1 |
Lymph node stage | ||||
pN0 | 69.3 | 47.8 | 90.3 | 89.5 |
pNx | 64.5 | 41.5 | 88.9 | 83.1 |
pN1–3 | 44.1 | 34.7 | 64.7 | 58.2 |
pT2 stage | ||||
LND status | ||||
LND | 50.1 | 27.3 | 75.6 | 67.3 |
No LND | 47.5 | 27.6 | 78.6 | 69.9 |
LND extent | ||||
No LND | 47.5 | 27.6 | 78.6 | 69.9 |
Limited LND | 48.6 | 29.7 | 73.3 | 64.0 |
Extended LND | 52.0 | 23.8 | 79.1 | 71.9 |
Lymph node stage | ||||
pN0 | 56.5 | 29.8 | 80.6 | 72.3 |
pNx | 47.5 | 27.6 | 78.6 | 69.9 |
pN1–3 | 22.9 | 16.3 | 51.6 | 42.9 |
pT3 stage | ||||
LND status | ||||
LND | 35.3 | 22.7 | 59.2 | 52.6 |
No LND | 36.2 | 22.1 | 62.4 | 55.6 |
LND extent | ||||
No LND | 36.2 | 22.1 | 62.4 | 55.6 |
Limited LND | 32.3 | 19.6 | 55.8 | 47.8 |
Extended LND | 39.6 | 24.5 | 63.9 | 60.4 |
Lymph node stage | ||||
pN0 | 43.8 | 26.6 | 69.3 | 63.3 |
pNx | 36.2 | 22.1 | 62.4 | 55.6 |
pN1–3 | 22.2 | 14.6 | 42.1 | 35.2 |
PT4 stage | ||||
LND status | ||||
LND | 13.9 | 8.6 | 31.8 | 30.2 |
No LND | 12.8 | 4.8 | 31.2 | 28.8 |
LND extent | ||||
No LND | 12.8 | 4.8 | 31.2 | 28.8 |
Limited LND | 15.1 | 8.3 | 36.6 | NA |
Extended LND | 11.5 | 9.2 | 23.8 | NA |
Lymph node stage | ||||
pN0 | 21.6 | 14.8 | 48.1 | NA |
pNx | 12.8 | 4.8 | 31.2 | 28.8 |
pN1–3 | 9.9 | 4.5 | 19.6 | NA |